Drugs / DW4421
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07691242 | Sep → Dec 2026 expected | — | Daewon Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07382661 | Feb → May 2026 overdue | — | Daewon Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07364877 | Dec 2025 → Mar 2026 overdue | — | Daewon Pharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07343245 | Dec 2025 → Feb 2026 overdue | — | Daewon Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07364838 | Nov 2024 → Apr 2025 | gastroesophageal reflux disease | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW4421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07382661 ↗ |
| Route | Oral | “A Randomized, Open-label, Oral in healthy volunteers” NCT07364838 ↗ |